&lt;p&gt;Minoxidil and its use in hair disorders: a review&lt;/p&gt;

Suchonwanit, Poonkiat; Thammarucha, Sasima; Leerunyakul, Kanchana

doi:10.2147/dddt.s214907

Cited by 255 publications

(217 citation statements)

References 87 publications

Supporting

Mentioning

165

Contrasting

Unclassified

Order By: Relevance

“…Among patients using minoxidil, dry skin, irritation, pruritis, and contact dermatitis were the most common reported side effects, 8,11 but were well tolerated by the majority of patients. Other adverse events induced by finasteride, LLLT and microneedling were rare in combined treatment groups.…”

Section: Discussionmentioning

confidence: 99%

“…Oral finasteride is only recommended for men and persistent sexual side effects were reported in some patients 10 . Topical minoxidil was the first product to be approved for the treatment of AGA in both men and women, of which the exact mechanism remains unclear, probably via increasing cutaneous blood flow 11 . Recently, complementary therapies including low‐level laser light therapy (LLLT), platelet‐rich plasma (PRP) and microneedling have been applied, and some suggested that combination treatment with topical minoxidil could be a promising strategy with better therapeutic efficacy than minoxidil monotherapy 12‐14 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effectiveness of combination therapies for androgenetic alopecia: A systematic review and meta‐analysis

Zhou

Chen

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Androgenetic alopecia (AGA) is the most common type of baldness affecting both men and women. Studies investigating combination therapies for AGA reported greater efficacy than monotherapy but without rigorous examination. The authors performed a meta‐analysis and systemic review to further verify the evidence. To evaluate the effectiveness of three common combination therapies of minoxidil with finasteride, low‐level laser light therapy (LLLT) or microneedling versus minoxidil monotherapy. We conducted a systematic review of randomized controlled trials (RCTs) of combination therapies consisting of topical minoxidil for AGA through April 2020. Quality assessment and data analysis were performed by Review Manager 5.3. Fifteen studies met the inclusion criteria involving a total of 1172 AGA patients. We conducted meta‐analysis for three groups of combined treatment separately, and all were superior to monotherapy in terms of global photographic assessment (P < .05). Combination of LLLT or microneedling with minoxidil also showed significant increase in hair count (P < .05) compared to monotherapy. The present study suggests that combination therapy could be an effective, safe and promising option for the treatment of AGA. However, more RCTs are needed to further investigate and confirm the efficacy of combined treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The effectiveness of combination therapies for androgenetic alopecia: A systematic review and meta‐analysis

Zhou

Chen

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Another substance acting against androgenic alopecia is minoxidil [ 98 ], which can give particularly promising results without side-effects when applied at a relatively low concentration [ 99 ]. Minoxidil was first introduced as an antihypertensive medication, but it is also used as an off-label treatment for androgenic alopecia.…”

Section: Potential Drug Targets and Active Substances In Novel Thementioning

confidence: 99%

In Search of New Therapeutics—Molecular Aspects of the PCOS Pathophysiology: Genetics, Hormones, Metabolism and Beyond

Wawrzkiewicz-Jałowiecka

Kowalczyk

Trybek

et al. 2020

IJMS

View full text Add to dashboard Cite

In a healthy female reproductive system, a subtle hormonal and metabolic dance leads to repetitive cyclic changes in the ovaries and uterus, which make an effective ovulation and potential implantation of an embryo possible. However, that is not so in the case of polycystic ovary syndrome (PCOS), in which case the central mechanism responsible for entraining hormonal and metabolic rhythms during the menstrual cycle is notably disrupted. In this review we provide a detailed description of the possible scenario of PCOS pathogenesis. We begin from the analysis of how a set of genetic disorders related to PCOS leads to particular malfunctions at a molecular level (e.g., increased enzyme activities of cytochrome P450 (CYP) type 17A1 (17α-hydroxylase), 3β-HSD type II and CYP type 11A1 (side-chain cleavage enzyme) in theca cells, or changes in the expression of aquaporins in granulosa cells) and discuss further cellular- and tissue-level consequences (e.g., anovulation, elevated levels of the advanced glycation end products in ovaries), which in turn lead to the observed subsequent systemic symptoms. Since gene-editing therapy is currently out of reach, herein special emphasis is placed on discussing what kinds of drug targets and which potentially active substances seem promising for an effective medication, acting on the primary causes of PCOS on a molecular level.

show abstract

“…Conventional formulations for topical MXD delivery comprise 5% minoxidil solution for hair application [22], which is associated with high levels of drug loss during the application procedure and low patient compliance to the treatment, which ultimately may result in the unreliable control of the dosage [23]. Additionally, the use of ethanol or propylene glycol-based solutions for conventional MXD formulations, manufactured to increase MXD's water solubility, can be associated with adverse The main aim of this review is to describe and critically analyze the drug delivery strategies applied in AGA, with a focus on MXD topical delivery systems, including conventional and, particularly, nanotechnology-based formulations.…”

Section: Conventional Formulations For Topical Delivery Of Minoxidilmentioning

confidence: 99%

Topical Minoxidil-Loaded Nanotechnology Strategies for Alopecia

et al. 2020

View full text Add to dashboard Cite

Androgenetic alopecia (AGA) is a multifactorial and age-related condition characterized by substantial hair loss affecting both men and women. Conventional treatments include the use of topical minoxidil (MNX) formulations to stimulate hair growth and restore hair condition. However, those treatments are associated with limited performance and a lack of tolerability and compliance due to the emergence of adverse effects. Considering that the development of nanotechnology-based formulations as hair loss therapeutic strategies has been clearly growing, topical MNX delivery by means of these innovative formulations is known to enhance MNX skin permeation and depot formation into hair follicles, allowing for MNX-controlled release, increased MNX skin bioavailability and enhanced therapeutic efficacy with minimal adverse effects. This review highlights the potential of nanotechnology-based MNX delivery formulations for improved hair loss therapeutics, including a thorough assessment of their in vitro and in vivo performances, as well as regulatory and nanosafety considerations.

show abstract

<p>Minoxidil and its use in hair disorders: a review</p>

Cited by 255 publications

References 87 publications

The effectiveness of combination therapies for androgenetic alopecia: A systematic review and meta‐analysis

The effectiveness of combination therapies for androgenetic alopecia: A systematic review and meta‐analysis

In Search of New Therapeutics—Molecular Aspects of the PCOS Pathophysiology: Genetics, Hormones, Metabolism and Beyond

Topical Minoxidil-Loaded Nanotechnology Strategies for Alopecia

Contact Info

Product

Resources

About